You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMefenamic acid
Accession NumberDB00784  (APRD00730)
TypeSmall Molecule
GroupsApproved
DescriptionA non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]
Structure
Thumb
Synonyms
Acide méfénamique
Acido mefenamico
Acidum mefenamicum
CI-473
CN 35355
CN-35355
INF 3355
INF-3355
Mefenaminsaeure
Mefenaminsäure
N-(2,3-Xylyl)-2-aminobenzoic acid
N-2,3-Xylylanthranilic acid
Ponstel
External Identifiers
  • CI 473
  • CN 35355
  • INF 3355
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-mefenamic Acidcapsule250 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Mefenamiccapsule250 mgoralAa Pharma Inc1996-11-06Not applicableCanada
Mefenamic Acidcapsule250 mg/1oralPrasco Laboratories2011-07-11Not applicableUs
Mefenamic-250capsule250 mgoralPro Doc Limitee1997-08-062009-07-23Canada
Novo-mefenamic Capsules 250mgcapsule250 mgoralNovopharm LimitedNot applicableNot applicableCanada
Nu-mefenamic 250 mgcapsule250 mgoralNu Pharm Inc1996-10-162012-09-04Canada
PMS-mefenamic Acidcapsule250 mgoralPharmascience Inc1998-04-16Not applicableCanada
Ponstancapsule250 mgoralErfa Canada 2012 Inc1966-12-31Not applicableCanada
Ponstelcapsule250 mg/1oralShionogi Inc.1967-03-28Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mefenamic Acidcapsule250 mg/1oralPaddock Laboratories, LLC2010-11-192016-03-01Us
Mefenamic Acidcapsule250 mg/1oralSolubiomix2016-03-23Not applicableUs
Mefenamic Acidcapsule250 mg/1oralQualitest Pharmaceuticals2014-06-02Not applicableUs
Mefenamic Acidcapsule250 mg/1oralBreckenridge Pharmaceutical, Inc.2014-10-13Not applicableUs
Mefenamic Acidcapsule250 mg/1oralBelcher Pharmaceuticals,LLC2015-06-25Not applicableUs
Mefenamic Acidcapsule250 mg/1oralLUPIN PHARMACEUTICALS INC2011-07-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CoslanParke Davis
LysalgoSIT
MefacitSecFarm
ParkemedPfizer
PonalarCoronet Crown
Ponstan FortePfizer
PonstylPfizer
Ponstyl FortPfizer
PontalDaiichi Sankyo
TanstonPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII367589PJ2C
CAS number61-68-7
WeightAverage: 241.2851
Monoisotopic: 241.110278729
Chemical FormulaC15H15NO2
InChI KeyInChIKey=HYYBABOKPJLUIN-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
IUPAC Name
2-[(2,3-dimethylphenyl)amino]benzoic acid
SMILES
CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Aminobenzoic acid
  • Benzoic acid
  • Substituted aniline
  • Benzoyl
  • Aniline
  • Vinylogous amide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
PharmacodynamicsMefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.
Mechanism of actionMefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
Related Articles
AbsorptionMefenamic acid is rapidly absorbed after oral administration.
Volume of distribution
  • 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
Protein binding90%
Metabolism

Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.

Route of eliminationThe fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.
Half life2 hours
Clearance
  • Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
ToxicityOral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mefenamic Acid Action PathwayDrug actionSMP00109
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.762
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7948
P-glycoprotein inhibitor INon-inhibitor0.8632
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.9191
CYP450 2C9 substrateNon-substrate0.6814
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7019
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9483
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9175
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6613
Ames testNon AMES toxic0.812
CarcinogenicityNon-carcinogens0.5833
BiodegradationNot ready biodegradable0.822
Rat acute toxicity2.5445 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9727
hERG inhibition (predictor II)Non-inhibitor0.8706
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 mg
Capsuleoral250 mg/1
Prices
Unit descriptionCostUnit
Ponstel 250 mg capsule11.85USD capsule
Mefenamic acid powder2.85USD g
Ponstel 250 mg kapseals1.59USD each
Apo-Mefenamic 250 mg Capsule0.52USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231 °CPhysProp
water solubility20 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.12HANSCH,C ET AL. (1995)
logS-3.78ADME Research, USCD
pKa4.2SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP4.58ALOGPS
logP5.4ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.89ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.88 m3·mol-1ChemAxon
Polarizability26.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AG01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (135 KB)
MSDSDownload (59.7 KB)
Interactions
Drug Interactions
Drug
AbciximabMefenamic acid may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Mefenamic acid can be increased when it is combined with Abiraterone.
AcebutololMefenamic acid may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Aceclofenac.
AcenocoumarolMefenamic acid may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mefenamic acid.
Alendronic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.
AliskirenMefenamic acid may decrease the antihypertensive activities of Aliskiren.
AlprenololMefenamic acid may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mefenamic acid.
AmikacinMefenamic acid may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMefenamic acid may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Mefenamic acid can be decreased when combined with Amiodarone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Mefenamic acid.
AncrodMefenamic acid may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Antipyrine.
Antithrombin III humanMefenamic acid may increase the anticoagulant activities of Antithrombin III human.
ApixabanMefenamic acid may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Apremilast.
AprepitantThe metabolism of Mefenamic acid can be increased when combined with Aprepitant.
ArdeparinMefenamic acid may increase the anticoagulant activities of Ardeparin.
ArgatrobanMefenamic acid may increase the anticoagulant activities of Argatroban.
ArotinololMefenamic acid may decrease the antihypertensive activities of Arotinolol.
AtenololMefenamic acid may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mefenamic acid.
BalsalazideMefenamic acid may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Mefenamic acid.
BecaplerminMefenamic acid may increase the anticoagulant activities of Becaplermin.
BefunololMefenamic acid may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mefenamic acid.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mefenamic acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Benoxaprofen.
BetaxololMefenamic acid may decrease the antihypertensive activities of Betaxolol.
BevantololMefenamic acid may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mefenamic acid.
BisoprololMefenamic acid may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMefenamic acid may increase the anticoagulant activities of Bivalirudin.
BopindololMefenamic acid may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bromfenac.
BufuralolMefenamic acid may decrease the antihypertensive activities of Bufuralol.
BumetanideMefenamic acid may decrease the diuretic activities of Bumetanide.
BupranololMefenamic acid may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mefenamic acid.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mefenamic acid.
CapecitabineThe metabolism of Mefenamic acid can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mefenamic acid.
CarbamazepineThe metabolism of Mefenamic acid can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mefenamic acid.
CarprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Carprofen.
CarteololMefenamic acid may decrease the antihypertensive activities of Carteolol.
CarvedilolMefenamic acid may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mefenamic acid.
CeliprololMefenamic acid may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Mefenamic acid can be increased when it is combined with Ceritinib.
CertoparinMefenamic acid may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefenamic acid.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mefenamic acid.
CholecalciferolThe metabolism of Mefenamic acid can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mefenamic acid.
Citric AcidMefenamic acid may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clonixin.
ClopidogrelThe metabolism of Mefenamic acid can be decreased when combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mefenamic acid.
ClotrimazoleThe metabolism of Mefenamic acid can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineMefenamic acid may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Mefenamic acid can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with D-Limonene.
Dabigatran etexilateMefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib.
DalteparinMefenamic acid may increase the anticoagulant activities of Dalteparin.
DanaparoidMefenamic acid may increase the anticoagulant activities of Danaparoid.
DaunorubicinMefenamic acid may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Deferasirox.
DeferasiroxThe serum concentration of Mefenamic acid can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Mefenamic acid can be decreased when combined with Delavirdine.
DesirudinMefenamic acid may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mefenamic acid.
DextranMefenamic acid may increase the anticoagulant activities of Dextran.
Dextran 40Mefenamic acid may increase the anticoagulant activities of Dextran 40.
Dextran 70Mefenamic acid may increase the anticoagulant activities of Dextran 70.
Dextran 75Mefenamic acid may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mefenamic acid.
DicoumarolMefenamic acid may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mefenamic acid.
DihydrostreptomycinMefenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mefenamic acid.
DoxorubicinMefenamic acid may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneMefenamic acid may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Droxicam.
Edetic AcidMefenamic acid may increase the anticoagulant activities of Edetic Acid.
EdoxabanMefenamic acid may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Mefenamic acid can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mefenamic acid.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mefenamic acid.
EnoxaparinMefenamic acid may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Epirizole.
EpirubicinMefenamic acid may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMefenamic acid may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mefenamic acid.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mefenamic acid.
EsmololMefenamic acid may decrease the antihypertensive activities of Esmolol.
Etacrynic acidMefenamic acid may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mefenamic acid.
Ethyl biscoumacetateMefenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Mefenamic acid.
EtofenamateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etoricoxib.
EtravirineThe metabolism of Mefenamic acid can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with exisulind.
FelodipineThe metabolism of Mefenamic acid can be decreased when combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mefenamic acid.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mefenamic acid.
FloxuridineThe metabolism of Mefenamic acid can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Mefenamic acid can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flunixin.
FluorouracilThe metabolism of Mefenamic acid can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mefenamic acid.
FluvastatinThe metabolism of Mefenamic acid can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Mefenamic acid can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mefenamic acid.
Fondaparinux sodiumMefenamic acid may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mefenamic acid.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mefenamic acid.
FosphenytoinThe metabolism of Mefenamic acid can be increased when combined with Fosphenytoin.
FramycetinMefenamic acid may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMefenamic acid may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mefenamic acid.
GemfibrozilThe metabolism of Mefenamic acid can be decreased when combined with Gemfibrozil.
GentamicinMefenamic acid may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.
HeparinMefenamic acid may increase the anticoagulant activities of Heparin.
HirulogMefenamic acid may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Mefenamic acid is combined with HMPL-004.
HydralazineMefenamic acid may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mefenamic acid.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mefenamic acid.
Hygromycin BMefenamic acid may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icatibant.
IdarubicinMefenamic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mefenamic acid.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mefenamic acid.
IndenololMefenamic acid may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Mefenamic acid can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.
IndoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mefenamic acid.
IsoxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Isoxicam.
KanamycinMefenamic acid may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Kebuzone.
KetoconazoleThe metabolism of Mefenamic acid can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mefenamic acid.
LabetalolMefenamic acid may decrease the antihypertensive activities of Labetalol.
LapatinibThe metabolism of Mefenamic acid can be decreased when combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Leflunomide.
LepirudinMefenamic acid may increase the anticoagulant activities of Lepirudin.
LevobunololMefenamic acid may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mefenamic acid.
LithiumThe serum concentration of Lithium can be increased when it is combined with Mefenamic acid.
LopinavirThe metabolism of Mefenamic acid can be decreased when combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mefenamic acid.
LovastatinThe metabolism of Mefenamic acid can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mefenamic acid.
LumacaftorThe serum concentration of Mefenamic acid can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mefenamic acid.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meloxicam.
MesalazineMefenamic acid may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mefenamic acid.
MetamizoleThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mefenamic acid.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.
MetipranololMefenamic acid may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid.
MetoprololMefenamic acid may decrease the antihypertensive activities of Metoprolol.
MetrizamideMefenamic acid may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Mefenamic acid can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mefenamic acid.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mefenamic acid.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mefenamic acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mefenamic acid.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Mefenamic acid.
NadololMefenamic acid may decrease the antihypertensive activities of Nadolol.
NadroparinMefenamic acid may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mefenamic acid.
NaproxenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Mefenamic acid is combined with NCX 4016.
NeomycinMefenamic acid may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nepafenac.
NetilmicinMefenamic acid may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Mefenamic acid can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Niflumic Acid.
NilotinibThe metabolism of Mefenamic acid can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mefenamic acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mefenamic acid.
OlsalazineMefenamic acid may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mefenamic acid.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mefenamic acid.
OmeprazoleThe metabolism of Mefenamic acid can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Orgotein.
OtamixabanMefenamic acid may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxaprozin.
OxprenololMefenamic acid may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Parecoxib.
ParomomycinMefenamic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololMefenamic acid may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateMefenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mefenamic acid.
PhenindioneMefenamic acid may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Mefenamic acid can be increased when combined with Phenobarbital.
PhenprocoumonMefenamic acid may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Phenylbutazone.
PhenytoinThe metabolism of Mefenamic acid can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mefenamic acid.
PindololMefenamic acid may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Mefenamic acid can be decreased when combined with Pioglitazone.
PiretanideMefenamic acid may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mefenamic acid.
PlicamycinMefenamic acid may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mefenamic acid.
PractololMefenamic acid may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mefenamic acid.
PrimidoneThe metabolism of Mefenamic acid can be increased when combined with Primidone.
ProbenecidThe serum concentration of Mefenamic acid can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Propacetamol.
PropranololMefenamic acid may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mefenamic acid.
Protein CMefenamic acid may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMefenamic acid may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Mefenamic acid is combined with PTC299.
PuromycinMefenamic acid may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Mefenamic acid can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mefenamic acid.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mefenamic acid.
QuinineThe metabolism of Mefenamic acid can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Mefenamic acid can be decreased when combined with Rabeprazole.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mefenamic acid.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mefenamic acid.
ResveratrolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.
ReviparinMefenamic acid may increase the anticoagulant activities of Reviparin.
RibostamycinMefenamic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Mefenamic acid can be increased when combined with Rifampicin.
RifapentineThe metabolism of Mefenamic acid can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Risedronate.
RitonavirThe metabolism of Mefenamic acid can be decreased when combined with Ritonavir.
RivaroxabanMefenamic acid may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Mefenamic acid.
RosiglitazoneThe metabolism of Mefenamic acid can be decreased when combined with Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mefenamic acid.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mefenamic acid.
SecobarbitalThe metabolism of Mefenamic acid can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Seratrodast.
SildenafilThe metabolism of Mefenamic acid can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Mefenamic acid can be decreased when combined with Sorafenib.
SotalolMefenamic acid may decrease the antihypertensive activities of Sotalol.
SpectinomycinMefenamic acid may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mefenamic acid.
SpironolactoneMefenamic acid may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Mefenamic acid is combined with SRT501.
StiripentolThe metabolism of Mefenamic acid can be decreased when combined with Stiripentol.
StreptomycinMefenamic acid may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMefenamic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Mefenamic acid can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Mefenamic acid can be decreased when combined with Sulfamethoxazole.
SulfasalazineMefenamic acid may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mefenamic acid.
SulfisoxazoleThe metabolism of Mefenamic acid can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mefenamic acid.
SulodexideMefenamic acid may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Suprofen.
TacrolimusMefenamic acid may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mefenamic acid.
TamoxifenThe metabolism of Mefenamic acid can be decreased when combined with Tamoxifen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mefenamic acid.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mefenamic acid.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mefenamic acid.
TenofovirThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mefenamic acid.
TepoxalinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Mefenamic acid can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Mefenamic acid can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tiludronate.
TimololMefenamic acid may decrease the antihypertensive activities of Timolol.
TobramycinMefenamic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Mefenamic acid can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mefenamic acid.
TorasemideMefenamic acid may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mefenamic acid.
TranilastThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mefenamic acid.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mefenamic acid.
TriamtereneMefenamic acid may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mefenamic acid.
TrimethoprimThe metabolism of Mefenamic acid can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mefenamic acid.
Valproic AcidThe metabolism of Mefenamic acid can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mefenamic acid.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mefenamic acid.
VoriconazoleThe metabolism of Mefenamic acid can be decreased when combined with Voriconazole.
WarfarinMefenamic acid may increase the anticoagulant activities of Warfarin.
XimelagatranMefenamic acid may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Mefenamic acid can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mefenamic acid.
Zoledronic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84. [PubMed:7832763 ]
  2. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study. Eur J Pharmacol. 2007 Feb 5;556(1-3):190-9. Epub 2006 Oct 27. [PubMed:17150210 ]
  3. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. Eur J Pharmacol. 2005 Mar 28;511(2-3):137-42. [PubMed:15792781 ]
  4. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21. [PubMed:9626023 ]
  5. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW, Powell JT: Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999 Jul 6;100(1):48-54. [PubMed:10393680 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Sinniah R, Lye WC: Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid. Clin Nephrol. 2001 Mar;55(3):254-8. [PubMed:11316248 ]
  2. Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, Chang KA, Kim S, Suh YH: Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol Pharmacol. 2006 Jan;69(1):76-84. Epub 2005 Oct 13. [PubMed:16223958 ]
  3. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21. [PubMed:9626023 ]
  4. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84. [PubMed:7832763 ]
  5. Laudanno OM, Cesolari JA, Esnarriaga J, Flaherty P, Vada J, Guastalli G, San Miguel P, Bedini OA: [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats]. Acta Gastroenterol Latinoam. 1998;28(3):249-55. [PubMed:9773153 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23